Phase 2 Clinical Trial Studying the Effectiveness and Safety of Elranatamab by Itself in Participants with Relapsed/Refractory Multiple Myeloma MAGNETISMM-3
Verified

What's the purpose of this trial?

The goal of this clinical trial is to study how effective and safe the study medicine, elranatamab, is for the potential treatment of relapsed/refractory multiple myeloma. Participants must have previously tried, but not had success with, at least three types of multiple myeloma treatments. 

This trial is currently open and accepting patients.


What will happen during the trial?

This clinical trial seeks to enroll approximately 150 patients, and will be organized into two separate groups, also called cohorts. Participants will be placed into one of two cohorts based on whether they have previously received therapies that target BCMA, a protein commonly found on the surface of multiple myeloma cells.

  • Cohort A (Currently Accepting Patients) will enroll about 90 patients who have never received therapies that target BCMA. 
  • Cohort B (Currently Accepting Patients) will enroll about 60 patients who have previously received therapies that target BCMA. 

If you’re interested in participating, you will review and sign the informed consent document and continue with the screening process, to confirm whether you’ve met all eligibility criteria. The screening period will take up to 28 days.

If you’ve met all eligibility criteria, the study’s treatment period begins. You will stay in the hospital for the first and second dose of the study medicine, so that your health can be monitored by the study team. The study medicine will be given by a medical professional as an injection under the skin. Everyone who takes part in the study will receive the study medicine (there is no placebo).

For the next six months, you will see the study doctor and receive the study medicine at weekly visits. The study team will perform physical exams and other tests to monitor your health. After the initial six months, the dosing schedule may be adjusted. If the study doctor sees that your multiple myeloma has progressed or if you experience any side effects that are difficult to manage, the study medicine will be discontinued.

Approximately one month after the last dose of study medicine, there will be a final visit so the study team can observe your health. After that, the study team will contact you by phone (or you may have a visit) about once every three months for up to five years to check on your health.

Reasonable travel arrangements, including hotel accommodations and ground transportation may be covered.  Please discuss this with the site staff for details.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • Have relapsed/refractory multiple myeloma, meaning that your multiple myeloma either has come back after responding to treatment, or hasn’t responded to treatment at all.
  • Among other things, participants must have tried, but not had success with, each of the following treatments:
    • At least 1 iMiD (immunomodulatory drug), such as lenalidomide or pomalidomide
    • At least 1 PI (proteasome inhibitor), such as bortezomib or carfilzomib
    • At least 1 anti-CD38 mAB (monoclonal antibody), such as daratumumab or isatuximab

If you are not sure which treatments you have received, please ask your doctor.


Additional Trial Information

Phase 2

Enrollment: 150 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

Beverly Hills Cancer Center

Beverly Hills, CA

Open and Accepting

Florida

Baptist Health Medical Group Oncology, LLC

Miami, FL

Not Yet Accepting

Miami Cancer Institute Baptist Health South Florida

Miami, FL

Open and Accepting

Indiana

Franciscan Health

Indianapolis, IN

Open and Accepting

Iowa

Holden Comprehensive Cancer Center University of Iowa Hospitals and Clinics

Iowa City, IA

Open and Accepting

Kentucky

Norton Cancer Institute St. Matthews Campus

Louisville, KY

Open and Accepting

Louisiana

Ochsner Foundation Clinic

Jefferson, LA

Not Yet Accepting

New York

Memorial Sloan Kettering Cancer Center

New York, NY

Open and Accepting

Roswell Park Cancer Institute

Buffalo, NY

Open and Accepting

Ohio

Pennsylvania

Fox Chase Cancer Center Temple Health

Philadelphia, PA

Open and Accepting

South Carolina

Prisma Health Boiling Springs

Boiling Springs, SC

Not Yet Accepting

Prisma Health Easley

Easley, SC

Not Yet Accepting

Saint Francis Hospital Cancer Center

Greenville, SC

Open and Accepting

Prisma Health Greenville Memorial Hospital

Greenville, SC

Open and Accepting

Prisma Health Greer

Greer, SC

Not Yet Accepting

Prisma Health Seneca

Seneca, SC

Not Yet Accepting

Trial Links

Read the latest news and updates on this trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Pfizer to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors